|Application ||WB, IHC, IF, FC, IP, E|
|Calculated MW||26kDa (core protein); 30-60kDa (glycosylated)|
|Other Names||CD63 antigen, Granulophysin, Lysosomal-associated membrane protein 3, LAMP-3, Melanoma-associated antigen ME491, OMA81H, Ocular melanoma-associated antigen, Tetraspanin-30, Tspan-30, CD63, CD63, MLA1, TSPAN30|
|Target/Specificity||Smooth plasma membrane fraction of MeWo cells|
|Application Note||ELISA : For coating, order Ab without BSA|
Flow Cytometry : 0.5-1ug/million cells
Immunofluorescence : 0.5-1.0 µg/ml
Western Blotting : 0.5-1.0 µg/ml
Immunoprecipitation : 0.5-1 µg/500ug protein lysate
Immunohistology (Frozen & Formalin-fixed) : 0.5-1.0 µg/ml for 30 minutes at RT
(Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10mM Citrate Buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes).
|Format||0.5 ml at 200ug/ml with BSA and azide|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||CD63 (Late Endosomes Marker) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Functions as cell surface receptor for TIMP1 and plays a role in the activation of cellular signaling cascades. Plays a role in the activation of ITGB1 and integrin signaling, leading to the activation of AKT, FAK/PTK2 and MAP kinases. Promotes cell survival, reorganization of the actin cytoskeleton, cell adhesion, spreading and migration, via its role in the activation of AKT and FAK/PTK2. Plays a role in VEGFA signaling via its role in regulating the internalization of KDR/VEGFR2. Plays a role in intracellular vesicular transport processes, and is required for normal trafficking of the PMEL luminal domain that is essential for the development and maturation of melanocytes. Plays a role in the adhesion of leukocytes onto endothelial cells via its role in the regulation of SELP trafficking. May play a role in mast cell degranulation in response to Ms4a2/FceRI stimulation, but not in mast cell degranulation in response to other stimuli.|
|Cellular Location||Cell membrane; Multi- pass membrane protein. Lysosome membrane; Multi-pass membrane protein. Late endosome membrane; Multi- pass membrane protein. Endosome, multivesicular body. Melanosome. Secreted, exosome. Cell surface. Note=Also found in Weibel-Palade bodies of endothelial cells (PubMed:10793155). Located in platelet dense granules (PubMed:7682577). Detected in a subset of pre- melanosomes. Detected on intralumenal vesicles (ILVs) within multivesicular bodies (PubMed:21962903)|
|Tissue Location||Detected in platelets (at protein level). Dysplastic nevi, radial growth phase primary melanomas, hematopoietic cells, tissue macrophages|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The tetraspanins are integral membrane proteins expressed on cell surface and granular membranes of hematopoietic cells and are components of multi-molecular complexes with specific integrins. The tetraspanin CD63 is a lysosomal membrane glycoprotein that translocates to the plasma membrane after platelet activation. CD63 is expressed on activated platelets, monocytes and macrophages, and is weakly expressed on granulocytes, T cell and B cells. It is located on the basophilic granule membranes and on the plasma membranes of lymphocytes and granulocytes. CD63 is a member of the TM4 superfamily of leukocyte glycoproteins that includes CD9, CD37 and CD53, which contain four transmembrane regions. CD63 may play a role in phagocytic and intracellular lysosome-phagosome fusion events. CD63 deficiency is associated with Hermansky-Pudlak syndrome and is strongly expressed during the early stages of melanoma progression.
1. C. Vennegoor et al., Int. J. Cancer 35: 287-295, 1985.
2. AA Palmer et al., Pathology 17: 335-339, 1985.
3. EC Hagen et al., Histopathology 10: 689-700, 1986.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.